Durvalumab for Esophageal Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Kansas Cancer Center, Westwood, KSEsophageal Cancer+3 MoreDurvalumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the safety of combining two drugs to treat gastroesophageal cancer and other gastrointestinal cancers. The goal is to find a more effective therapy for these patients.

Eligible Conditions
  • Stomach Cancer
  • Esophageal Cancer
  • Liver Cancer
  • Colorectal Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: Every 8 weeks for 12 months

18 months
Overall Benefit Rate (OBR)
Proportion of participants with adverse events (AEs).
24 months
Overall Survival (OS)
Progression Free Survival (PFS)
9 months
Phase I- Maximum Tolerated Dose (MTD)
Month 12
Phase II- Overall Response Rate (ORR)

Trial Safety

Safety Progress

1 of 3

Trial Design

4 Treatment Groups

Cabozantinib plus Durvalumab (Gastric & esophageal cancer cohort)
1 of 4
Cabozantinib plus Durvalumab (Hepatocellular carcinoma cohort)
1 of 4
Cabozantinib plus Durvalumab (Colorectal cancer cohort)
1 of 4
Cabozantinib plus Durvalumab plus Tremelimumab (Hepatocellular carcinoma cohort)
1 of 4

Experimental Treatment

117 Total Participants · 4 Treatment Groups

Primary Treatment: Durvalumab · No Placebo Group · Phase 1 & 2

Cabozantinib plus Durvalumab (Gastric & esophageal cancer cohort)Experimental Group · 2 Interventions: Durvalumab, Cabozantinib · Intervention Types: Drug, Drug
Cabozantinib plus Durvalumab (Hepatocellular carcinoma cohort)Experimental Group · 2 Interventions: Durvalumab, Cabozantinib · Intervention Types: Drug, Drug
Cabozantinib plus Durvalumab (Colorectal cancer cohort)Experimental Group · 2 Interventions: Durvalumab, Cabozantinib · Intervention Types: Drug, Drug
Cabozantinib plus Durvalumab plus Tremelimumab (Hepatocellular carcinoma cohort)Experimental Group · 3 Interventions: Durvalumab, Tremelimumab, Cabozantinib · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Durvalumab
FDA approved
Tremelimumab
Not yet FDA approved
Cabozantinib
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: every 8 weeks for 12 months

Who is running the clinical trial?

Anwaar SaeedLead Sponsor
1 Previous Clinical Trials
34 Total Patients Enrolled
AstraZenecaIndustry Sponsor
4,017 Previous Clinical Trials
240,372,350 Total Patients Enrolled
ExelixisIndustry Sponsor
109 Previous Clinical Trials
17,873 Total Patients Enrolled
Anwaar Saeed, MD5.02 ReviewsPrincipal Investigator - The University of Kansas Cancer Center
University of Kansas Medical Center
3 Previous Clinical Trials
62 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 15 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have an advanced stage of cancer that cannot be removed by surgery.

Frequently Asked Questions

What are the most common conditions that doctors use Durvalumab to manage?

"The therapeutic benefits of Durvalumab have been observed in patients with a pre-existing condition, those who have received anti-vegf treatments, and those who supplement their amino acids." - Anonymous Online Contributor

Unverified Answer

Does this program still have room for more participants?

"That is accurate. The clinical trial in question, which can be found on clinicaltrials.gov, is seeking patients at the moment. This specific study was posted on October 22nd, 2018 and updated as recently as May 8th, 2022. There is a total goal of 117 patients across 1 location." - Anonymous Online Contributor

Unverified Answer

What other research exists on this topic?

"AstraZeneca first began sponsoring research into Durvalumab in 2007. That year, the drug underwent its first clinical trial. After Phase 2 approval was granted in 2007, following a 37 person study, today there are 501 active trials involving Durvalumab being conducted across 2003 cities and 60 countries." - Anonymous Online Contributor

Unverified Answer

What is the extensive history of Durvalumab in previous medical research?

"501 clinical trials are being conducted for Durvalumab globally. Out of these, 67 are in Phase 3. Port Huron, Michigan is the city with the most studies, however there are 26413 locations running at least one trial for this medication." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.